FORCE’s eXamining the Relevance of Articles for Young Survivors (XRAYS) program is a reliable resource for breast cancer research-related news and information. XRAYS reviews new breast cancer research, provides plain-language summaries, and rates how the media covered the topic. XRAYS is funded by the CDC.
Men with breast cancer
Triple negative breast cancer
Her2+ breast cancer
People with a genetic mutation linked to cancer risk
Breast cancer survivors
Women under 45
Women over 45
Healthy people with average cancer risk
Special populations: women with early-stage breast cancer
Hormonal therapy significantly reduces the risk of recurrence for women with early-stage estrogen receptor-positive breast cancer. Standard hormonal therapy is given for 5 years; extending that therapy for a longer period offers additional protection but has added side effects. This study looked at women who stopped hormonal therapy after 5 years and identified factors that may guide the decision to extend treatment. (12/21/17)
|At a glance||In-depth|
|Clinical trials||Resources and references|
|Questions for your doctor|
Standard treatment for early-stage breast cancer often includes 5 years of endocrine-based (hormonal) treatments such as tamoxifen or aromatase inhibitors (both are pills that are taken daily). The aim of this study was to learn which patients could stop hormonal therapy after 5 years because their risk of recurrence would be very small. However, this study found that even for women believed to be at low risk of recurrence, breast cancer recurrences continued steadily for up to 20 years after diagnosis. This study identified which features of a patient’s original cancer influence long-term risk of recurrence. These findings may help guide the decision of whether or not to extend standard hormonal therapy beyond 5 years.
In women diagnosed with early-stage ER-positive breast cancer who stopped endocrine therapy after the standard 5 years of treatment, breast cancer recurrence occurred at a steady rate from 5 to 20 years. Over the study period, risk of recurrence was strongly linked to the original cancer's size and to the number of positive lymph nodes at the time of diagnosis.
The results of this study may help identify which early-stage ER-positive breast cancer patients would most benefit from extending hormonal therapy beyond the standard 5 years of treatment. However, the benefits of extending endocrine therapy must be weight against side effects. The findings of this study underline the need to help women who are receiving endocrine therapy to discover whether any side effect symptoms are actually caused or made worse by therapy.
Modern Medicine Network
Researchers of this study attempted to identify women whose long-term risk of recurrence was so small that any additional benefit from extended therapy would not be outweighed by added side effects. Hongchao Pan, PhD, and colleagues conducted a meta-analysis of 88 trials involving 62,923 women with ER-positive breast cancer who were disease free after 5 years of endocrine therapy. They used data on recurrence, tumor diameter and nodal status (TN), tumor grade and other factors during 5 to 20 years after standard endocrine therapy ended. Results were published in the November 9, 2017 edition of the New England Journal of Medicine.
Whether they could identify women with early-stage, ER-positive breast cancer who were disease free following 5 years of standard endocrine therapy for whom additional benefit from extended therapy would not outweigh added side effects. However, they revealed factors that may help to guide patients and healthcare providers when considering who would benefit from extended hormonal therapy.
Researchers analyzed data from 88 clinical trials involving 62,923 women with ER-positive breast cancer.
The cumulative risk and annual rates of distant recurrence and death from breast cancer in each 5-year period from year 0 to year 20, was subdivided according to lymph node status at the time of diagnosis. In each category, distant recurrence occurred steadily throughout the 20-year period. Annual risk was strongly related to nodal status.
The annual rates of death from breast cancer, as would be predicted in a population that was disease free following 5 years of endocrine therapy, was low during the first 5 years. However, starting at year 5, the annual rates of death increased. These risks were not significantly lower than the 20-year risk of distant recurrence.
However, even women with small, node-negative (T1N0) low-grade tumors had risk of distant recurrence. For these women (T1N0) risk of recurrence was:
The corresponding risk of any recurrence or contralateral breast cancer for these women (T1N0) was:
When other factors were taken into account, tumor grade and Ki-67 status were moderate independent predictive indicators for recurrence. Progesterone receptor and HER2 receptor status did not predict recurrence.
The risk for recurrence steadily rose among women who were diagnosed with early-stage ER-positive breast cancer, received 5 years of hormonal therapy and were disease-free when their therapy ended. Risk of recurrence was strongly associated with the original size of the tumor and the patient’s nodal status at the time of diagnosis. These findings impact long-term follow-up strategies and the need for new approaches to reduce the long-term risk of recurrence. For some patients, risk may be reduced by extending the duration of hormonal therapy; however, additional side effects of extended therapy must be taken into consideration. Tumor size and lymph node involvement at the time of diagnosis may help to identify those who would benefit the most from extended endocrine therapy.
Share your thoughts on this XRAYS article by taking our brief survey
FORCE Information: Breast Cancer Treatment
Pan H, Gray R, Braybrooke J, et al. “20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.” New England Journal of Medicine 2017;377:1836-46.